On Monday, Swiss pharmaceutical giant Roche stated, it has hired a professor from the Massachusetts Institute of Technology (MIT) as its new head of its U.S. research arm which was responsible for some of it’s best-selling medicines in the last… Read More ›
According to a Channel 4 news bulletin, Roche has struck a deal with Britain to increase the country’s testing capacity for the Wuhan coronavirus. The report, cites Britain’s health authority Public Health England as saying, the new COVID-19 testing machines… Read More ›
Swiss drugmaker Roche has won approval from U.S. antitrust authorities for its $4.3 billion bid to acquire gene therapy specialist Spark Therapeutics. The development clears the way for Roche’s strategic push to position itself in the treatment of rare diseases,… Read More ›
In a statement the Bill & Melinda Gates Foundation stated, its Chief Executive Sue Desmond-Hellmann will be stepping down after more than five years, and Mark Suzman will be replacing her. Desmond-Hellmann stated, she was stepping down from the Gates… Read More ›
The decision comes in the wake of continuing regulatory scrutiny by antitrust regulators in the UK and U.S. over its takeover offer. Following a continuation of regulatory reviews in the United States and Britain, Roche and Spark Therapeutics announced another… Read More ›
The Swiss drugmaker’s board is seeing some reshuffles, including on at its diagnostics business, which had been held by Michael Heuer on an interim basis. On Tuesday, Swiss drugmaker Roche announced changes to its board and executive leadership. Longtime director… Read More ›
He will be replaced by Michael Heuer, Roche’s regional head of Europe, the Middle East, Africa, and Latin America, until a permanent replacement is found. On Tuesday, Roche disclosed, Roland Diggelmann the head of its diagnostics division will be leaving… Read More ›
Sanofi’s strength in molecular oncology is likely to provide it a competitive edge over its peers as to what drives the growth of cancer tissues, how these cells functions and proliferation in the body. In a strategic development, French drugmaker,… Read More ›
Ignyta’s precision drugs and diagnostic portfolio will help Roche increase its global footprint in the oncology department. On Friday, U.S. cancer drugmaker Ignyta Inc and Swiss drugmaker Roche disclosed that the Swiss pharmaceutical giant will acquire U.S. drugmaker for $1.7… Read More ›
manageria.biz 